Beone Medicines revenue and financials
Secondary listing. The primary listing is BeOne Medicines · NASDAQ (USD)
$219.60Change from previous close: +0.46%Absolute change: +$1.00
In the fiscal year ended December 2025, Beone Medicines reported revenue of $5.34B (+40.23% year over year). Net income was $286.93M, a net margin of 5.4%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +40.23%
- 2025 vs 2024
- Net margin
- 5.4%
- 2024: -16.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 5,343 | 3,810 | 2,459 | 1,416 | 1,176 | 309 | 428 | 198 | 238 | 1.1 |
| Cost of revenue | — | — | — | 286 | 165 | 70.7 | 71.2 | 28.7 | 5.0 | 0.0 |
| Gross profit | 4,674 | 3,216 | 2,079 | 1,129 | 1,011 | — | — | — | — | — |
| Research and development | 2,146 | 1,953 | 1,779 | 1,641 | 1,459 | 1,295 | 927 | 679 | 269 | 98.0 |
| Operating income | 447 | -568 | -1,208 | -1,790 | -1,439 | -1,658 | -960 | -706 | -98.5 | -117 |
| Income tax | 130 | 112 | 55.9 | 42.8 | 19.2 | 10.4 | 7.0 | -15.8 | 2.2 | 0.1 |
| Net income | 287 | -645 | -882 | -2,004 | -1,458 | -1,625 | -949 | -674 | -93.1 | -119 |
| Basic EPS | 0.20 | -0.47 | -0.65 | -1.49 | -1.21 | -1.50 | -1.22 | — | — | — |
| Diluted EPS | 0.19 | -0.47 | -0.65 | -1.49 | -1.21 | -1.50 | -1.22 | — | — | — |
| Average shares (diluted) | 1,475 | 1,369 | 1,357 | 1,341 | 1,206 | 1,085 | 781 | — | — | — |